Last €37.58 EUR
Change Today +0.001 / 0.00%
Volume 0.0
AG8 On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 9:44 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

agilent technologies inc (AG8) Snapshot

Open
€37.64
Previous Close
€37.58
Day High
€37.64
Day Low
€37.43
52 Week High
09/18/14 - €46.45
52 Week Low
12/16/14 - €30.49
Market Cap
12.6B
Average Volume 10 Days
235.8
EPS TTM
--
Shares Outstanding
335.8M
EX-Date
01/2/15
P/E TM
--
Dividend
€0.37
Dividend Yield
1.01%
Current Stock Chart for AGILENT TECHNOLOGIES INC (AG8)

agilent technologies inc (AG8) Details

Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The company’s Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; nuclear magnetic resonance, magnetic resonance imaging, and X-ray diffraction systems; immunohistochemistry; in situ hybridization; hematoxylin and eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation and gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems. Its Chemical Analysis segment provides gas chromatography systems, columns, and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; inductively coupled plasma optical emission spectrometry instruments; molecular spectroscopy instruments; software and data systems; and vacuum pumps and measurement technologies. Agilent Technologies, Inc. sells its products through direct sales; and distributors, resellers, manufacturer's representatives, telesales, and electronic commerce. The company was founded in 1999 and is headquartered in Santa Clara, California.

12,000 Employees
Last Reported Date: 02/17/15
Founded in 1999

agilent technologies inc (AG8) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $1.1M
President and Chief Operating Officer
Total Annual Compensation: $606.3K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $600.0K
Executive Vice President, Chief Executive Off...
Total Annual Compensation: $795.8K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2014.

agilent technologies inc (AG8) Key Developments

Agilent Technologies Inc. Launches OneSeq Target Enrichment Product

Agilent Technologies Inc. has launched OneSeq, a target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research. Powered by Agilent's SureSelect target-enrichment platform, the new OneSeq constitutional research panel will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data.

Agilent Technologies Inc. Introduces Two Products to Advance Clinical Cancer Research

Agilent Technologies Inc. launched two new products, the HaloPlexHS target enrichment system and ClearSeq Comprehensive Cancer research panel designed to improve the speed and accuracy of clinical cancer research. Both products will enable researchers to rapidly and accurately identify disease-associated variants in tumor samples information that can be vital to research in cancer treatments. The company is showcasing its new products at the annual Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, this week. HaloPlexHS Target Enrichment System: HaloPlexHS is a high-sensitivity amplicon-based targeted sequencing method based on Agilent’s innovative HaloPlex technology. This new method enables clinical researchers to meet one of their most daunting challenges: accurately identifying low-frequency somatic variants in solid tumors and hematological cancers. One of the first commercially available high-sensitivity target-enrichment technologies for next-generation sequencing, HaloPlexHS incorporates more than 1 million unique molecular barcodes for accurate detection of alleles at low frequencies. The molecular barcodes are especially important for cancer researchers who work with heterogeneous samples in which driver mutations can be present in subclonal cell populations. ClearSeq Comprehensive Cancer Panels: ClearSeq, an off-the-shelf cancer research panel developed in collaboration with researchers at Washington University, provides an accelerated solution for the analysis of many oncogenes and tumor suppressors. This panel is the latest addition to Agilent’s growing portfolio of ClearSeq cancer research panels and targets 151 key oncology genes containing disease-associated variants. Designed with the clinical researcher in mind, the new panel allows clinical researchers to rapidly profile multiple mutations present in cancer samples.

Agilent Technologies Inc. Launches SureVector, Innovative Cloning Kit

Agilent Technologies Inc. introduced SureVector, modular vector kit for researchers involved in molecular cloning and DNA assembly. Harnessing the efficiency of next-generation DNA assembly technologies, SureVector provides a synthetic biology-based approach to creating vectors from small fragments of DNA that include the features to make these vectors functional in a variety of cell types. Laboratories that rely on service providers to create custom vectors often pay high per-unit costs and must endure long lead times. The alternative, ordering DNA fragments and assembly enzymes separately, leaves the lab to toil with DNA/enzyme combinations that have not been validated and may require extensive troubleshooting. With SureVector, on the other hand, Agilent provides an extensively validated set of standardized parts that can be assembled into thousands of combinations covering a huge portion of commercially available vectors. This new product is part of Agilent’s cutting-edge synthetic biology product line, which includes both the highest-fidelity DNA synthesis platform and advanced measurement instruments such as mass spectrometry systems. SureVector follows QuikChange HT and the SureGuide CRISPR/Cas system as the latest in a series of next-generation tools for the molecular and synthetic biology community.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AG8:GR €37.58 EUR +0.001

AG8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AMETEK Inc $53.18 USD +0.04
NVIDIA Corp $22.34 USD +0.28
NXP Semiconductors NV $96.89 USD +11.99
Sigma-Aldrich Corp $138.03 USD -0.03
STMicroelectronics NV €8.15 EUR +0.171
View Industry Companies
 

Industry Analysis

AG8

Industry Average

Valuation AG8 Industry Range
Price/Earnings 29.4x
Price/Sales 2.0x
Price/Book 3.3x
Price/Cash Flow 37.2x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGILENT TECHNOLOGIES INC, please visit www.home.agilent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.